Fiscal 2013 Overview *Sales and year-on-year changes are based on J-GAAP. Net sales including revenues related to export products and licenses, etc.  in Japan decreased by 1.2% year on year to ¥550.7 billion. Sales in the  Japanese market were ¥535.6 billion, mostly unchanged from the previ- ous fiscal year, as the impact of generics was largely offset by steady  expansion in sales of growing mainstay products and new products. By product, growing sales of Betanis contributed with Vesicare to the  further expansion of our share of the overactive bladder (OAB) treatment  market. In addition to Betanis, products such as Micardis (including its  combination drugs, Micombi and Micamlo), Celecox, Symbicort, Bonoteo  and vaccines showed growth in sales. There were also contributions from  sales of new products including Cimzia and Gonax. Sales of some prod- ucts declined, including Lipitor, Seroquel and Myslee, mainly due to the  impact of generics. Micamlo BP, Acofide, Bisono Tape and Irribow OD  were launched in fiscal 2013. Fiscal 2014 Outlook *Sales and year-on-year changes are based on IFRS. For fiscal 2014, we project a 0.4% year-on-year decrease in domestic  sales to ¥528.4 billion. This estimate includes only a slight fall in sales in  Japan’s prescription market to ¥508.3 billion, as the impact of NHI drug  price revisions are expected to be offset partly by sales of growing prod- ucts and new products. We expect sales contributions from Suglat and  XTANDI, which were launched in April and May 2014, respectively. Note: Yen base *Calculated according to the location of sellers *IFRS EMEA 23.2% Asia & Oceania 5.1% Japan 46.5% Sales by Geographical Area 2014.3 Americas 25.2% Net Sales (Japanese Market Sales) (¥ billion) 600 450 300 150 0 2012.3 2013.3 2014.3 2015.3 (Forecast) J-GAAP IFRS Japan We will launch a steady stream of new products as we push  ahead to become the leader in Japan in terms of quantity and quality. L  Review of Global Operations Astellas Pharma Inc.  _ Annual Report 2014 44